Schrödinger Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•16:05 ET
0
Key Highlights
- ➤ACV $44.7 million, up 17% year over year
- ➤Total revenue $64.5 million, up 19% year over year
- ➤Drug discovery revenue $24.2 million, versus $13.0 million, boosted by Structure milestone
- ➤Full-year 2026 ACV guidance raised to $222 million to $232 million
- ➤Full-year drug discovery revenue guidance raised to $75 million to $85 million
Expert Statements
Ramy Farid, Chief executive officer of Schrödinger
“We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each other. Applying our platform to complex drug discovery and materials science challenges gives us direct insight that continuously enhances our computational platform. At the same time, our sustained track record of delivering on high-impact programs gives our partners the confidence to expand their software commitments. The continuous feedback loop is building durable value across our business.”
Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance
Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.